Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global Th17 driven disease treatment market is anticipated to register strong growth between 2020 and 2030.
Psoriasis to Remain Primary Indication Pushing Th17 Driven Disease Treatment Market Demand
The latest Fact.MR report offers actionable and valuable insights on the Th17 driven disease treatment market. It provides a thorough analysis of growth drivers, restrains, opportunities and emerging trends shaping the market dynamics across key regions. To present the information in a coherent manner, the report has been segmented on the basis of indication, drug and distribution channel across major regions.
Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global Th17 driven disease treatment market is anticipated to register strong growth between 2020 and 2030. The overall sales are poised to rise at a significant rate amid rising penetration of novel drugs across emerging economies.
Growing health awareness, rising spending on medicines, advances in medical research and increasing prevalence of Th17 driven disease such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and asthma are some of the factors driving the global market.
Th17 cells play a crucial role in enhancing the host defense against extracellular pathogens, particularly at the mucosal and epithelial barriers. However, under certain conditions, these cells are associated with the pathogenesis of several autoimmune and inflammatory diseases such as psoriasis and rheumatoid arthritis. As a result, various drugs are being recommended to treat these diseases.
Increasing consumption of Th17 driven disease drugs such as calcipotriol and azathioprine is the major factor boosting the growth of the market.
Get Sample Copy With Impact Analysis Of COVID-19 Of Market Report
https://www.factmr.com/connectus/sample?flag=B&rep_id=5284
Further, continuous drug approvals by regulatory bodies will continue to expand the Th17 driven disease treatment market. Moreover, key market players are investing vigorously in research activities to expand the therapeutic application of the Th17 driven disease treatment drugs. This is expected to bode well for the market during the assessment period.
Additionally, increasing penetration of online pharmacies across attractive regions along with expanding pharmaceutical industry will help the market players to capitalize in the global Th17 driven disease treatment market.
As per Fact.MR, psoriasis segment will account for the largest revenue share through 2030. Rising prevalence of psoriasis worldwide is the primary factor boosting the sales of Th17 driven disease drugs.
According to the World Psoriasis Day consortium, an estimated 125 Mn people have psoriasis globally.
Regionally, North America is likely to retain its dominant position in the global Th17 driven disease treatment market during the forecast period. Growth in the region is attributed to rising patient pool, increasing spending on medicines, strong presence of key players and continuous advances in drug development research.
“Faster regulatory approvals have lend a huge thrust for the acceleration of Th17 driven disease treatment market and the trend is likely to continue in future. Key players are aiming at penetrating attractive markets by developing more effective and affordable drugs,” says a Fact.MR analyst
Key Takeaways from Th17 Driven Disease Treatment Market Survey
- North America will continue to dominate the Th17 driven disease treatment market on account of increasing cases of rheumatoid arthritis, multiple sclerosis and several other diseases.
- With expanding healthcare infrastructure, increasing research activities and rising spending on medicines, Europe will emerge as the second most lucrative market for Th17 driven disease treatment.
- Asia is poised to exhibit strong growth as a result of increasing drug approvals and rising government support.
- Based on indication, psoriasis treatment segment is likely to dominate the Th17 driven disease treatment market during the forecast period.
- By distribution channel, hospital pharmacies segment will account for the largest revenue share through 2030.
Key Drivers
- Increasing penetration of online pharmacies will continue to boost the market.
- Growing awareness among people regarding the effectiveness of Th17 driven disease treatment will augment the sales during the forecast period.
- Presence of favorable reimbursement structure in healthcare industry is expected to support the growth in the market.
Key Restraints
- Limited availability of medication for Th17 driven disease is restraining the growth.
- High cost of available Th17 driven disease drugs might limit the growth.
To gain in-depth insights on Th17 Driven Disease Treatment Market, request methodology at
https://www.factmr.com/connectus/sample?flag=RM&rep_id=5284
Competitive Landscape
Leading players operating in the Th17 driven disease treatment market are heavily investing in research and development activities. They have adopted various growth strategies such as new drug development & approvals, acquisitions, mergers and partnerships to increase their sales.
- In December 2021, AbbVie received the U.S. Food and Drug Administration (FDA) approval of RINVOQ (upadacitinib) for the treatment of adults with active psoriatic arthritis.
- In September 2021, Mayne Pharma announced that it has received the U.S. FDA approval of LEXETTE for the treatment of plaque psoriasis in patients aged 12 years and older.
- In January 2021, Kyowa Kirin Co., Ltd. announced that LEO Pharma K.K. has received an approval for manufacturing and marketing Dovobet Foam for the treatment of psoriasis vulgaris. The approval enhances the company’s product portfolio.
- In December 2021, Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology and InveniAI LLC, a global leader in applying artificial intelligence (AI) and machine learning (ML) to transform drug discovery and development, expanded their longstanding relationship with a new drug discovery agreement.
- In May 2019 Mayne Pharma received FDA approval for SORILUX for adolescent plaque psoriasis. SORILUX Foam contains calcipotriene, a synthetic vitamin D analog that has a similar receptor binding affinity as natural vitamin D.
Some of the prominent players operating in the Th17 driven disease treatment market profiled by Fact.MR are:
- AbbVie
- Alexion Pharmaceuticals
- Alder Biopharmaceuticals
- Astellas Pharma.
- Others
More Insights on the Global Th17 Driven Disease Treatment Sales Outlook
Fact.MR provides an unbiased analysis of Th17 driven disease treatment market, presenting historical demand data (2015-2019) and forecast statistics for the period from 2020-2030. The study divulges compelling insights on the global demand for Th17 driven disease treatment with a detailed segmentation on the basis of:
Indication
- Psoriasis
- Rheumatoid Arthritis
- Multiple Sclerosis
- Inflammatory Bowel Disease
- Asthma
Drug
- Gentamicin
- Azathioprine
- Calcipotriol
- Trolamine salicylate
- Histamine
- Capsaicin
Distribution Channel
- Hospital pharmacies
- Pharmacies
- Online pharmacies
Key Questions Covered in the Th17 Driven Disease Treatment Market Outlook Report
- The report offers insight into Th17 driven disease treatment demand outlook for 2020-2030
- The market study also highlights projected sales growth for Th17 driven disease treatment market between 2020 and 2030
- Th17 driven disease treatment market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Th17 driven disease treatment market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain –
Asthma Treatment Market Insights - Asthma therapeutics are expected to see increased demand as patients become more aware of their ailment. This should have resulted in a linear rise of the asthma treatment market; however, a surge in generic medicine sales, fueled by branded drug patent expiration, is expected to limit market potential. North America is expected to maintain its lead in the asthma treatment market, while Asia Pacific is expected to grow at the quickest rate. North America would lose market share to Asia Pacific throughout the projection period.
Arthritis Therapeutics Market Forecast - Rapid introduction of biologics brings new commercial prospects for companies in the arthritis therapeutics market. Given the influence of favorable reimbursement scenarios that cushion the high cost, biologic medicine uptake is strong, particularly in developed countries of North America, Europe, and Asia Pacific. As a result of the high success rate of arthritis therapeutics, manufacturers are investing large sums to research and development, ensuring the continued availability of blockbuster pharmaceuticals.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.
MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
You can access all our healthcare research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR